SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
CANCER: KAPOSI SARCOMA & KAPOSI SARCOMA–ASSOCIATED HERPESVIRUS, CERVICAL, LUNG, BREAST, LYMPHOMA, AND HEAD & NECK
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
8 of
8
|
THE PERSISTENCE OF HIV-ASSOCIATED KAPOSI SARCOMA: ANALYSES OF US MEDICARE POPULATION (ABSTRACT
475)
Ramya Ramaswami
National Cancer Institute, Bethesda, MD, USA
HPV GENOTYPE AND FAILURE AFTER TREATMENT OF CERVICAL PRECANCER (ABSTRACT
476)
Christina Carlander
Karolinska Institutet, Solina, Sweden
CERVICAL CANCER PREVENTION DURING COVID-19 PANDEMIC: THE CRS EPIC3-90 PROJECT, ZAMBIA (ABSTRACT
477)
Mwate Joseph Chaila
Catholic Relief Services, Lusaka, Lusaka, Zambia
TREATMENT TOXICITY FOR LUNG CANCER PATIENTS WITH AND WITHOUT HIV INFECTION (ABSTRACT
478)
Keith Sigel
Icahn School of Medicine at Mount Sinai, New York, NY, USA
GYNAECOLOGICAL AND BREAST CANCERS IN WOMEN LIVING WITH HIV IN SOUTH AFRICA (ABSTRACT
479)
Tafadzwa G Dhokotera
Swiss Tropical and Public Health Institute, Basel, Basel City, Switzerland
PHASE 1 STUDY OF LENALIDOMIDE WITH EPOCH AND RITUXIMAB IN PRIMARY EFFUSION LYMPHOMA (ABSTRACT
480)
Kathryn Lurain
National Cancer Institute, Bethesda, MD, USA
ALTERED TUMOR MICROENVIRONMENT AND REDUCED SURVIVAL IN HIV+ HEAD AND NECK CANCERS (ABSTRACT
481)
Syim Salahuddin
Yale School of Medicine, New Haven, CT, USA
H3K27ME3 PREVENTS ABERRANT TRANSCRIPTION AND EPISOME CLEARANCE OF KSHV (ABSTRACT
482)
Simon Weissmann
Heinrich Pette Institute - Leibniz Institute for Experimental Virology, Hamburg, Germany
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
8 of
8
|
